Clinical and molecular insights into the hepatocellular carcinoma tumour marker des‐γ‐carboxyprothrombin
Open Access
- 27 September 2010
- journal article
- review article
- Published by Wiley in Liver International
- Vol. 31 (1), 22-35
- https://doi.org/10.1111/j.1478-3231.2010.02348.x
Abstract
Des‐γ‐carboxyprothrombin (DCP) is known as a tumour marker for hepatocellular carcinoma (HCC). Various tumour markers have been developed for serological diagnosis of cancers, including HCC, in order to increase the survival rate of cancer patients. The currently recommended combined testing of DCP and α‐fetoprotein (AFP) or Lens culinaris agglutinin‐reactive fraction of α‐fetoprotein has been established to diagnose HCC. This combined testing using several tumour markers helps to increase the sensitivity of diagnosis of HCC, thus significantly increasing the clinical usefulness of DCP. The excessive production of DCP may be related to worse tumour behaviour, such as the presence of vascular invasion and intrahepatic metastasis of HCC cells. A high level of DCP was suggested to be useful as one of the factors in new recipient selection criteria of liver transplantation. The clinical use of DCP, therefore, might play a vital role in predicting tumour behaviour in patients with HCC. That said, the basic mechanism of DCP production has not been fully clarified. Various factors such as vitamin K2 and γ‐glutamyl carboxylase may contribute to the production of DCP and have a complex relationship. Moreover, recent studies have revealed that DCP functions as a growth factor and might play significant roles in cancer progression. Thus, DCP represents a potential target of drug discovery to establish new chemotherapeutic strategy for HCC. However, various issues have to be resolved to construct a novel therapy for HCC‐targeting DCP. Innovation is required to make further progress in examining DCP.Keywords
This publication has 73 references indexed in Scilit:
- α-Fetoprotein, Des-γ Carboxyprothrombin, and Lectin-Bound α-Fetoprotein in Early Hepatocellular CarcinomaGastroenterology, 2009
- Des-γ-carboxy prothrombin stimulates human vascular endothelial cell growth and migrationClinical & Experimental Metastasis, 2009
- Des-gamma-carboxy prothrombin increases the expression of angiogenic factors in human hepatocellular carcinoma cellsLife Sciences, 2008
- Sorafenib in Advanced Hepatocellular CarcinomaNew England Journal of Medicine, 2008
- AFP, PIVKAII, GP3, SCCA-1 and follisatin as surveillance biomarkers for hepatocellular cancer in non-alcoholic and alcoholic fatty liver diseaseBMC Cancer, 2008
- Complete remission of hepatocellular carcinoma with portal vein tumor thrombus and lymph node metastases by arterial infusion of 5-fluorouracil and interferon-α combination therapy following hepatic resectionThe Esophagus, 2007
- Des-γ-carboxyl Prothrombin-promoted Vascular Endothelial Cell Proliferation and MigrationPublished by Elsevier BV ,2007
- Combination of vitamin K2 and the angiotensin-converting enzyme inhibitor, perindopril, attenuates the liver enzyme-altered preneoplastic lesions in rats via angiogenesis suppressionJournal of Hepatology, 2005
- Clinical evaluation of plasma des-?-carboxy prothrombin as a marker protein of hepatocellular carcinoma in patients with tumors of various sizesDigestive Diseases and Sciences, 1993
- Des-γ-Carboxy (Abnormal) Prothrombin as a Serum Marker of Primary Hepatocellular CarcinomaNew England Journal of Medicine, 1984